{
  "drug_name": "Cefoxitin",
  "tradename": "Mefoxin",
  "usage_and_dosing": {
    "general": [
      "Cefoxitin is a 2nd-generation parenteral cephamycin cephalosporin.",
      "Increasing resistance of anaerobic Gram-negative bacilli (e.g., Bacteroides sp.) has been observed.",
      "In vitro may induce increased áºž-lactamase, especially in Enterobacter sp.",
      "For class-wide adverse effects and other information, see Cephalosporins, Overview."
    ],
    "adult_dose": {
      "usual_dose": "2 gm IV q6-8h"
    },
    "pediatric_dose": {
      "dose_age_gt_28_days": "80-160 mg/kg/day (divided q6-8h)",
      "max_day": "-"
    }
  },
  "renal_adjustment": {
    "notes": "May falsely increase Scr by interference with assay.",
    "half_life_normal": "0.8",
    "half_life_esrd": "13-23",
    "dose_renal_function_normal": "2 gm IV q8h",
    "crcl_or_egfr": "CrCl >50: No dosage adjustment. CrCl 10-50: 2 gm q8-12h. CrCl <10: 2 gm q24-48h",
    "hemodialysis": "2 gm q24-48h (+ extra 1 gm AD)",
    "capd": "1 gm q24h",
    "crrt": "2 gm q8-12h",
    "sled": "No data"
  },
  "hepatic_adjustment": {
    "mild_impairment_child_pugh_a": "No dosage adjustment",
    "moderate_impairment_child_pugh_b": "No dosage adjustment",
    "severe_impairment_child_pugh_c": "No dosage adjustment"
  },
  "other_adjustment": {
      "obesity": "For surgical prophylaxis, larger dose possibly required. Data insufficient for a firm recommendation. See Obesity Dosing Adjustments table for more information."
  },
  "adverse_effects": [
    "Local phlebitis (rare), fever, rash (2%), positive Coombs (2%), neutropenia (2%), eosinophilia (3%), increased PT/PTT, GI (2%), C. difficile colitis, increased LFTs (3%), increased BUN/Creatinine (3%)."
  ],
  "pregnancy_risk": {
    "fda_risk_category": "No evidence of toxicity in humans or animals",
    "lactation": "Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",
    "footnote": "Capital letter = Old FDA risk category; Text = New FDA risk category"
  },
  "antimicrobial_spectrum": {
    "preferred": [],
    "alternative": []
  },
  "pharmacology": {
    "pk_pd_index": "T>MIC",
    "preparations": "Injection",
    "food_recommendation": null,
    "oral_absorption_percent": null,
    "tmax_hr": null,
    "peak_serum_conc_ug_ml": "110 (1 gm IV, SD)",
    "peak_urine_conc_ug_ml": "No data",
    "protein_binding_percent": "65-79",
    "volume_of_distribution_vd_l_vss": "16.1 L (Vss)",
    "avg_serum_half_life_hr": "0.8",
    "elimination": "Renal",
    "bile_penetration_percent": "280",
    "csf_blood_percent": "3",
    "therapeutic_levels_in_csf": "No",
    "auc_ug_hr_ml": "No data"
  },
  "major_drug_interactions": [
    "No significant interactions."
  ],
  "comments": [
    "None"
  ]
}
